Clinical Trials Logo

Clinical Trial Summary

Heart failure (HF) is the leading cause of death in US. It is associated with abnormal vascular function termed endothelial dysfunction. It is also associated with increased stress on the blood vessels and high levels of inflammation. Vagus nerve stimulation can help improve inflammation, vascular function and vascular stress. The investigator has recently completed a study showing that 1 hour of noninvasive vagus stimulation can improve vascular health. However, it is unknown if 8 weeks of stimulation will be beneficial in systolic heart failure.

The purpose of this study is to determine if transcutaneous vagal stimulation (TVS) will lead to improvement in the function of the inner lining of participants' arteries, memory, and in the levels of certain chemical markers of arterial function in the blood.

Participants will be randomized to receive either TVS or a sham stimulation and undergo 8 weeks of stimulation. Vascular function will be assessed by several non-invasive measurements, including Flow Mediate Dilation (FMD), Pulse Wave Analysis (PWA), EndoPAT, and Laser Speckle Contrast Imaging (LSCI). Participants' memory will also be measured through electronic assessments and blood will be collected and analyzed for arterial function chemical markers.

Clinical Trial Description

Visit 1: Following tests(to assess vascular function) will be done: 1. FMD 2) LSCI 3) EndoPAT and 4) Pulse wave analysis (PWA). Patients will rest for 10 minutes between each test. They will be trained to use PARASYMTM unit for TVS. Blood collected, serum/plasma will be stored at -80F. Whole blood will be collected in PAXgene tubes. Patients will be instructed to apply TVS to either ear lobule (SHAM) or Tragus(experimental arm). Baseline characteristics will be collected including data on ventricular function(LVEF and left ventricular volumes).

Visit 2 (8 weeks): Follow up tests(FMD,LSCI,EndoPAT,PWA) and repeat blood collection.

Inflammatory cytokines and vascular function assays will be performed. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03945058
Study type Interventional
Source University of Oklahoma
Contact Tarun Dasari, MD
Phone 4052714742
Status Not yet recruiting
Phase N/A
Start date June 1, 2019
Completion date May 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03614169 - Direct HIS-pacing as an Alternative to BiV-pacing in Symptomatic HFrEF Patients With True LBBB N/A
Active, not recruiting NCT03701880 - Early Use of Ivabradine in Heart Failure N/A
Enrolling by invitation NCT03479424 - Home Outpatient Monitoring and Engagement to Predict HF Exacerbation
Completed NCT02113033 - VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients Phase 2
Recruiting NCT03209180 - Immediate Release Versus Slow Release Carvedilol in Heart Failure Phase 4
Completed NCT03870074 - CPET Predicts Long-term Survival and Positive Response to CRT
Completed NCT03951740 - Validation of Two Wrist-worn Devices for the Assessment of Energy Expenditure in Cardiac Patients. N/A
Recruiting NCT03894683 - Effect of Melatonin on Cardiovascular and Muscle Mass and Function in Patients With Heart Failure Phase 2
Completed NCT01922089 - Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Phase 2
Recruiting NCT03644446 - Bisoprolol Plasma Residual Concentrations in Chronic Heart Failure
Recruiting NCT03746938 - First in Humans to Evaluate Collagen Patches With Stem Cells in Patients With Ischemic Left Ventricular Dysfunction Phase 1
Not yet recruiting NCT03213821 - Safety and Efficacy of High Protein Diet Versus GFR Based Protein Diet in Heart Failure Patients With Renal Insufficiency N/A
Not yet recruiting NCT03332888 - Safety of HMA-CD20 in Patients With HFrEF Phase 2
Recruiting NCT03141567 - LYmphangiogenesis FacTors in Heart Failure States
Not yet recruiting NCT03877887 - Finding Gab in the Treatment of Heart Failure in Assiut University Hospital
Recruiting NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Recruiting NCT03235700 - Hyperemic Efficacy of IV Adenosine in HFrEF N/A
Recruiting NCT03198585 - Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction Phase 2
Enrolling by invitation NCT03574857 - Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Phase 4
Recruiting NCT03136029 - Exercise and NO in HFrEF Early Phase 1